Publications by authors named "M-E Taplin"
Article Synopsis
- The study investigates how AI-generated measurements of intraprostatic tumor volume from MRI scans can predict the risk of metastasis in prostate cancer patients treated with either radiation therapy or radical prostatectomy.
- A total of 732 patients were involved, with findings indicating that a larger tumor volume significantly correlated with increased rates of metastasis during the follow-up periods, which averaged 6.9 years for radiation therapy and 5.5 years for surgery.
- The research highlighted that the AI-based volume measurements provided independent prognostic information, outperforming traditional risk categorization methods in predicting long-term metastasis.
Metastatic castration-resistant prostate cancer is typically lethal, exhibiting intrinsic or acquired resistance to second-generation androgen-targeting therapies and minimal response to immune checkpoint inhibitors. Cellular programs driving resistance in both cancer and immune cells remain poorly understood. We present single-cell transcriptomes from 14 patients with advanced prostate cancer, spanning all common metastatic sites.
View Article and Find Full Text PDFGenomic correlates of clinical outcome in advanced prostate cancer.
Proc Natl Acad Sci U S A
June 2019
Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, we report comprehensive genomic and transcriptomic analysis of 429 patients with metastatic castration-resistant prostate cancer (mCRPC) linked with longitudinal clinical outcomes, integrating findings from whole-exome, transcriptome, and histologic analysis. For 128 patients treated with a first-line next-generation androgen receptor signaling inhibitor (ARSI; abiraterone or enzalutamide), we examined the association of 18 recurrent DNA- and RNA-based genomic alterations, including androgen receptor () variant expression, AR transcriptional output, and neuroendocrine expression signatures, with clinical outcomes.
View Article and Find Full Text PDFBackground: Inherited mutations in DNA-repair genes such as BRCA2 are associated with increased risks of lethal prostate cancer. Although the prevalence of germline mutations in DNA-repair genes among men with localized prostate cancer who are unselected for family predisposition is insufficient to warrant routine testing, the frequency of such mutations in patients with metastatic prostate cancer has not been established.
Methods: We recruited 692 men with documented metastatic prostate cancer who were unselected for family history of cancer or age at diagnosis.
Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor (AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but agents targeting ErbB2 have not been effective. This study was undertaken to assess ErbB2 activity in abiraterone-resistant prostate cancer and to determine whether it may contribute to AR signaling in these tumors.
Experimental Design: AR activity and ErbB2 signaling were examined in the radical prostatectomy specimens from a neoadjuvant clinical trial of leuprolide plus abiraterone and in the specimens from abiraterone-resistant CRPC xenograft models.